Experts weigh in on a rapidly evolving treatment landscape, from a first-line oral option to a one-time CRISPR therapy showing 87% attack reduction.
Mauro Cancian, MD, PhD
Advertisement
Mauro Cancian, MD, PhD, head of the allergy division at the University of Padua.
Articles by Mauro Cancian, MD, PhD
Updated HAE guidelines support early self-treatment; Cancian discuss transitioning patients from injectable on-demand therapy to oral sebetralstat after KONFIDENT data.
KONFIDENT investigator Cancian discusses oral sebetralstat’s role in the updated HAE treatment guidelines.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Biologics in Asthma and COPD: Real-World Gaps, Outcomes, and Unmet Needs
2
Shared Decision-Making Guides Epinephrine Delivery Choice
3
GLP-1s in Dermatology: Emerging Evidence and Unanswered Questions
4
Dupilumab, Depemokimab, and COPD: What APPs See in Practice
5